This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Moderna's (MRNA) Investors Losing Wealth: What Lies Ahead?
by Zacks Equity Research
Moderna's (MRNA) stock has been on a declining trend since August 2021 after a strong rally since the beginning of 2020.
The Zacks Analyst Blog Highlights: Mastercard Inc., Pfizer Inc. and Citigroup Inc
by Zacks Equity Research
Mastercard Inc., Pfizer Inc. and Citigroup Inc are included in this blog.
The Zacks Analyst Blog Highlights: Eli Lilly, Regeneron Pharmaceuticals, Pfizer and Merck
by Zacks Equity Research
Eli Lilly, Regeneron Pharmaceuticals, Pfizer and Merck are included in this blog.
The Zacks Analyst Blog Highlights: Pfizer, Merck, Eli Lilly, Regeneron and Gilead
by Zacks Equity Research
Pfizer, Merck, Eli Lilly, Regeneron and Gilead are included in this analyst blog.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $52.54 in the latest trading session, marking a +1.94% move from the prior day.
The Zacks Analyst Blog Highlights: Roche Holding, Pfizer, Baxter International, STMicro and Philips
by Zacks Equity Research
Roche Holding, Pfizer, Baxter International, STMicro and Philips are included in this analyst blog.
Earnings Season Scorecard and Analyst Reports for Mastercard, Pfizer & Citigroup
by Sheraz Mian
Today's Research Daily features a real-time update on the Q4 earnings season and new research reports on 12 major stocks, including Mastercard Incorporated (MA), Pfizer Inc. (PFE), and Citigroup Inc. (C).
Merck's (MRK) Chronic Cough Drug Gets CRL From FDA
by Zacks Equity Research
Merck's (MRK) new drug application for gefapixant to treat refractory chronic cough or unexplained chronic cough fails to secure approval from the FDA. Meanwhile, the drug secures approval in Japan.
4 Top-Ranked High Earnings Yield Picks to Add to Your Kitty Now
by Rimmi Singhi
Royal Dutch Shell (RDS.A), Goodyear Tire (GT), Pfizer (PFE) and Crocs, Inc. (CROX) could be some attractive bets if you are looking for high earnings yield picks.
FDA Limits Use of Regeneron & Lilly's COVID Antibody Cocktails
by Zacks Equity Research
The FDA modifies EUA for COVID-19 antibody cocktail drugs of Regeneron (REGN) and Lilly (LLY), limiting their use to treat individuals with COVID-19 infection from non-Omicron variants.
J&J (JNJ) Q4 Earnings Beat Estimates by a Penny, Sales Miss
by Zacks Equity Research
J&J (JNJ) reports mixed fourth-quarter results. It beats estimates for earnings but misses the same for sales.
Large Cap Pharma, Biotech Stocks Down on Regulatory Updates
by Zacks Equity Research
Pharma giants like Pfizer (PFE), Merck (MRK) and Eli Lilly (LLY), along with biotech bigwig Regeneron (REGN), are down on regulatory updates.
Best Growth Stocks to Buy for January 25th
by Zacks Equity Research
CROX, M, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 25, 2022
Pfizer's (PFE), OPKO's BLA for Somatrogon Gets CRL From FDA
by Zacks Equity Research
The FDA issues a Complete Response Letter to Pfizer (PFE) and OPKO Health's biologics license application for somatrogon to treat growth hormone deficiency in pediatric patients.
Oxygen from Earnings: Global Week Ahead
by John Blank
In the Global Week Ahead, Q4 S&P500 earnings will supply the latest details on how major global companies are dealing with rising wage cost pressures.
Gilead (GILD) Drug Gets FDA Nod for Non-Hospitalized COVID Patients
by Zacks Equity Research
Gilead (GILD) gets FDA approval for label expansion of Veklury for the treatment of non-hospitalized patients at high risk for COVID-19 disease progression.
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Psoriatic Arthritis
by Zacks Equity Research
AbbVie (ABBV) secures approval in the United States for Skyrizi to treat adult patients with active psoriatic arthritis.
Best Growth Stocks to Buy for January 24th
by Zacks Equity Research
WLK, PFE, and M made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 24, 2022
Nuvation (NUVB) Gets FDA Clearance for Oncology Candidate
by Zacks Equity Research
Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination with Lynparza or Xtandi in multiple tumor types following IND clearance by the FDA.
Pharma Stock Roundup: GSK's Consumer Unit Offer Rejection, FDA Updates for AZN, PFE
by Kinjel Shah
Glaxo (GSK) rejects a $68 billion buyout offer for its consumer healthcare unit from Unilever. FDA updates for Pfizer (PFE), AbbVie (ABBV) and AstraZeneca (AZN) grab headlines.
OPKO's (OPK) NGENLA Approved by Japan's MHLW for GHD Treatment
by Zacks Equity Research
Latest approval for OPKO's (OPK) NGENLA is expected to reduce the treatment frequency from daily injections, thereby better serving the GHD patient pool.
Best Growth Stocks to Buy for January 21st
by Zacks Equity Research
PFE, M, and ARCB made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 21, 2022
Sanofi (SNY) 2nd Dupixent Prurigo Nodularis Study Meets Goal (Revised)
by Zacks Equity Research
Sanofi's (SNY) PRIME is the second successful study on Dupixent for the prurigo nodularis indication.
Sanofi (SNY) 2nd Dupixent Prurigo Nodularis Study Meets Goal
by Zacks Equity Research
Sanofi's (SNY) PRIME is the second successful study on Dupixent for the prurigo nodularis indication.
Glaxo (GSK) Stock Down As Unilever Decides Not to Raise Offer
by Zacks Equity Research
Unilever decides that it will not raise its offer of $68 billion for Glaxo's (GSK) Consumer Healthcare business.